Background In clinical studies, pathogen inactivation (PI) of platelet concentrates (PC) with amotosalen and UVA light did not impact patient risk for haemorrhage but may affect transfusion frequency and component utilization. We evaluated the influence of platelet PI on PC, red cell concentrate (RCC) and plasma use and safety in routine practice in a large regional hospital.
Introduction
Platelet concentrates (PC) are used to prevent bleeding and to treat active haemorrhage in thrombocytopaenic patients, or in those with congenital or acquired functional platelet defects. PC's contribute substantially to patient costs and carry the risks of bacterial contamination, transmission of infectious diseases, alloimmunization and graft-versus-host disease (GVHD), all of which necessitate their judicial use. In early 2013, the University Hospital, Innsbruck (UHI) Austria, introduced universal PI of whole blood (WB)-buffy coat (BC) and apheresis platelets with amotosalen and UVA light (INTERCEPT Blood System, Cerus Europe BV, Amersfoort, The Netherlands) (PI-PC) to mitigate bacterial and other infectious risks and to replace gamma irradiation for prevention of GVHD [1, 2] . The UHI is a 1600 bed regional hospital with active cardiac surgery, organ and haematopoietic stem cell transplant programmes, utilizing approximately 39 700 RCC; 4035 apheresis PC; 1400 pooled BC PC; and 12 500 plasma transfusions in 2015. The blood bank within the UHI provides all PC and RCC for transfusion and supports the region of Tyrol. In this setting, active haemovigilance was used to evaluate the impact of PI implementation on blood component utilization and patient safety.
Therapeutic efficacy of PI-PC has been demonstrated in clinical trials, including the randomized, controlled SPRINT study [3] in which 645 haematology/oncology patients with chemotherapy-induced thrombocytopaenia were evaluated. The incidence of grade 2, 3 and 4 bleeding assessed were equivalent using the WHO bleeding scale. The mean 1-h platelet CCI (16Á0 9 10 3 control vs. 11Á1 9 10 3 test), mean number of days to next platelet transfusion (2Á4 control vs.1Á9 test) and mean number of platelet transfusions (6Á2 control vs. 8Á4 test) were different (P < 0Á01). These observations raised the possibility that the use of amotosalen/UVA treatment may increase PC utilization; however, postmarketing studies have not documented an increase [4, 5] . The objectives of this study were to characterize PC, RCC and plasma utilization after adoption of PI-PC as an indirect measure of platelet efficacy in comparison to conventional PC transfused prior to amotosalen/UVA implementation, as well as to evaluate the safety profile assessed by transfusion-related adverse events. Comparative effectiveness studies of this nature allow the assessment of efficacy in a greater number and variety of patients than is feasible in randomized controlled trials and may provide additional data about the safety profile of novel blood products.
Materials and methods

Study design
This was a two treatment-period cohort design study. All patients receiving PC transfusion at UHI for 21 months before (control period: 1 April 2011 -31 December 2012) and after (test period: 1 April 2013 -31 December 2014) implementation of PI treatment using the INTERCEPT Blood System (amotosalen/UVA) for platelets were included in the analysis. Patient demographics, component characteristics and transfusion-related AE were extracted from the blood bank electronic medical record. Patients were transfused with PC based on the clinicians' assessment of their clinical condition and a peripheral blood platelet count of less than 20 000/ll in nonbleeding patients. In general, transfusion trigger practices did not change over the two periods of the study, except that thromboelastometry (ROTEM, Tem International GmbH, M€ unchen, Germany) was increasingly used as a basis for evaluating coagulation status and the need for transfusion in cardiac surgical patients during the study period. PC were used to support patients in all hospital departments, and the data for RCC and plasma utilization are summarized for patients who received any platelet transfusion. There were no restrictions on the use of pathogen inactivated platelets in any patient groups, including neonates. UV therapy lights used in the neonatal units were confirmed not to emit light within the absorption spectrum of amotosalen. All individual components were analysed as separate transfusion events, regardless of the intervening time period. We investigated potential changes in component utilization in all patients, and in haematology/oncology, cardiac surgery, paediatric and neonatal subpopulations. 'Haematology/oncology' includes patients who received any PC transfusion in the adult and children's haematology/oncology wards or in the radiation therapy department. 'Cardiac surgery' includes patients who received any PC transfusion in the cardiac surgery wards or cardiac operating theatre areas. Paediatric patients, many of whom are also included in the haematology/oncology or cardiac surgery subpopulations, were ≤18 years old and include neonates who were ≤30 days at the time of their first transfusion. A total of 91 patients received PC during both the control and test periods.
Collection and preparation of PC
Platelets were collected on Trima (Terumo BCT, Zaventem, Belgium) or Amicus (Fresenius Kabi, Bad Homberg, Germany) apheresis separators, or prepared from pools of five BC concentrates separated from WB collections after room temperature overnight storage. All final components were leucocyte reduced and suspended in approximately 35% plasma and 65% SSP+ platelet additive solution (PAS) (Macopharma, Tourcoing, France) during both periods. During the control period, apheresis and BC platelet pools were subjected to gamma irradiation for the prevention of transfusion-associated GVHD when requested by their physician and universally screened for bacterial contamination using the BacT/ALERT culture system (bioMerieux, Marcy-L'Etoile, France). Briefly, for apheresis platelets, samples for culture screening were taken 18-24 h after collection and, for BCs, on day 1 after viral marker results were received and BC were pooled. Six millilitre (ml) samples were inoculated into both aerobic and anaerobic bacterial culture bottles and monitored for 7 days. Products were released into inventory for transfusion immediately after sampling and stored for up to 5 days. For PC still in inventory on day 4, shelf life was extended following BacT/ALERT reculture, allowing for relabelling with a 7-day shelf life on day 5. For amotosalen/UVA treatment in the test period, large volume (LV) and dual storage (DS) processing kits were used. PC containing 2Á5-8Á0 9 10 11 platelets were treated with amotosalen (nominal final concentration 150 lM) and 3 J/cm 2 UVA according to the manufacturer's instructions for use, followed by incubation on a compound absorption device (CAD) for 6-16 h. Apheresis components were generally treated on the day of collection (day 0), and products were released into inventory the next day on receipt of the viral testing results. For BC pools, amotosalen/UVA treatment was performed immediately after BC pool preparation and the PC could be released into inventory after incubation on a compound absorption device (CAD). PI-PC were stored for up to 7 days before transfusion [6] . Amotosalen/UVA-treated platelets were not subject to gamma irradiation.
Safety monitoring
A standard reporting form was issued with each blood component released for transfusion. Clinicians were required to report the outcomes of all transfusions regardless of outcome, and the results are recorded in the electronic medical record. Compliance with this requirement was consistently greater than 90% over the study. For transfusions associated with AE, a local coding system was used to describe the symptoms and a responsible doctor from the blood bank investigated and classified each reaction considered related to the transfusion into two categories: mild or severe. All severe transfusionrelated AE were reported to the regulatory authority (AGES).
Statistical analysis
Data were summarized descriptively by mean, standard deviation, median and range for continuous data or by frequencies and proportions (%) for categorical data, using SAS â version 9.3 (SAS Institute, Cary, NC, USA).
All control PC and test PI-PC administered to a patient in each of the two study periods were included in the full analysis population, and data were summarized on a pertransfusion basis and a per-patient basis. PC transfusion utilization, in terms of the average number of days of PC support and intertransfusion intervals, was analysed only during courses of active support, defined as all PC transfusions that preceded an hiatus a 5 or more days, signifying platelet transfusion independence. Significance (P values <0Á05) for the between-period differences were calculated with a two-tailed t-test assuming unequal variances for continuous variables. The Fisher's exact test was used for categorical variables. For days of platelet support, the mean difference was assessed using a negative binomial distribution.
Results
Patient demographics
During the control period, 1797 patients received 8611 conventional PC components. The majority of the patient population was male (64Á6%, Table 1 ) with a mean age of 57Á9 years (range <1-93), and 8Á7% of the patients were in the paediatric age group (≤18 years) including 56 (3Á1%) under 1 year and 23 (1Á3%) in the neonatal (≤30 days) age group. The largest subpopulation receiving PC support was cardiac surgery patients (739, 41Á1%), and the second largest were haematology/oncology patients (522, 29Á0%). During the test period, the patient demographics were not different with respect to gender, age or distribution at the time of their first PC transfusion: 1694 patients received 7705 PI-PC components, majority were male (66Á4%) with a mean age of 58Á5 years (range <1-92), 711 (42Á0%) and were treated in the cardiac surgery and 452 (26Á7%) in the haematology/oncology departments: 130 (7Á7%) of these patients were children (≤ 18 years old) including 46 (2Á7%) under 1 years, and 20 (1Á2%) patients were neonates. Haematology/oncology patients received the largest proportion of PC during both the control and test periods, respectively (5126, 59Á5% vs. 4070, 52Á8%), followed by cardiac surgery patients (1881, 21Á8% vs. 1821, 23Á6%). Together these two groups used~76% of all PC transfused.
Platelet concentrate characteristics
Most PC were ABO matched during both the control and test periods (73Á9% vs. 73Á0%, P = 0Á20) ( Table 2 ). The proportion of BC-pooled platelets was intentionally increased from 8% during the control period to 25% during the test period to help reduce costs. Wastage of PC was low (<2%) during both periods. The average collection dose of apheresis platelets was 5Á89 10 11 in the control, and 5Á9 9 10 11 (prior to treatment with amotosalen/ UVA) in the test period. Collections with dose yields greater than 5Á0 x10 11 were split into two doses. In the test period, this occurred after PI treatment. Doses that were not sufficient to split were transfused as single doses with 2Á5-4Á9 9 10 11 platelets before treatment. Validation data revealed that the WB-BC platelets contained a mean of 3Á29 10 11 platelets before amotosalen/UVA treatment.
Actual dose transfused after amotosalen/UVA treatment was not recorded; however, we aimed at an average dose of platelets of~3Á0 x10 11 per component for both periods and for both apheresis and BC platelets.
The mean PC age at transfusion was statistically different between the study periods (control = 3Á4 days vs. test = 3Á5 days, P < 0Á01). The majority of PC were transfused after ≤5 days of storage and the median age was 3Á0 days during both periods. However, more PC were transfused greater than 5 days old during the test period (control = 9Á5% vs. test = 15Á5%, P = <0Á01). The PC age at transfusion was evaluated separately for components received by haematology/oncology patients (control = 3Á5 days vs. test = 3Á8 days, P < 0Á01), paediatric patients (control = 3Á3 days vs. test = 3Á5 days, P < 0Á01) and neonates (control = 2Á7 days vs. test = 3Á7 days, P < 0Á01). In contrast, the mean age of PC for cardiac surgery patients was the same (3Á3 days, P = 0Á51) in both periods.
Utilization of platelet concentrates
PC use was evaluated during courses of active platelet support, defined as transfusions that occurred in clusters before a 5-day interval signifying platelet transfusion independence ( Table 3 ). The mean number of PC received for all patients was the same for the control and test periods (4Á8 vs. 4Á5 PC/patient, P = 0Á44) (Table 3) . Overall, the number of courses of active support (mean control = 1Á5 vs. test = 1Á4, P = 0Á04) and the days of PC support (control = 5Á9 vs. test = 5Á0, P < 0Á01) were lower during the test period, while the average interval between transfusions was not different (control = 0Á9 vs. test = 0Á8 days, P = 0Á07). When the subpopulations were analysed, there were no differences in the PC use per patient, number of PC support courses, average intertransfusion interval or days of platelet support between the control and test periods in the cardiac surgery and neonatal subgroups; however, the paediatric group had a lower mean number of PC/patient (mean 7Á3 vs 4Á1 PC/ patient, P = 0Á02) and both the haematology/oncology (control = 14Á7 vs. test = 12Á3, P = 0Á03) and paediatric groups (control = 10Á7 vs. test = 5Á5, P < 0Á01) had fewer days of PC support in the test period. The latter was mostly related to a decrease in the number of paediatric haematology/oncology patients undergoing stem cell transplants during the test period. PC usage overall was greatest in haematology/oncology patients (9Á8 vs. 9Á0 PC/patient, P = 0Á41) ( Table 3) . Patients undergoing cardiac surgery received fewer PC than the overall population (mean 2Á5 vs. 2Á6 PC/patient, P = 0Á93) ( Table 3 ). The frequency distribution of the number of PC received per patient was not different (P > 0Á05) between the study periods, overall or in the subgroups; however, in both study periods, the distribution was notably different between haematology/oncology and cardiac surgery patients. The majority of cardiac surgery patients received ≤2 PC components (median = 1Á0) in a single transfusion episode (average intertransfusion interval <1Á0 day) while most haematology/oncology patients received ≤3 PC (median 4Á0), often in several courses of platelet support over many days.
Utilization of red cell concentrates and plasma
86Á8% of control and 84Á8% (P = 0Á10) of test patients who received a PC also received at least one RCC, and the mean number of RCC received was not different between cohorts (control = 10Á8 vs. test = 10Á2 RCC/patient; P = 0Á22) ( Table 4) . Mirroring the experience with PC utilization, RCC usage was greatest for haematology/oncology patients (control = 13Á7 vs. test = 13Á0; P = 0Á53) and less in cardiac surgery patients (control = 7Á3 vs. test = 7Á1; P = 0Á80). RCC use in the paediatric population (control = 7Á7 vs. test = 6Á3; P = 0Á12) was similar to the cardiac surgery population while use in neonates (control = 4Á1 vs. test = 5Á5; P = 0Á61) tended to be lower. The proportion of patients receiving any RCC was not statistically significantly different in the control and test periods for any subgroup.
In contrast, mean plasma utilization by patients receiving PC, prepared as quarantined plasma, methylene blue-treated plasma (Macopharma, Tourcoing, France) or solvent detergent plasma (Octaplas, Octapharma, Wien, Austria), was lower during the test period (control = 9Á9 vs. test = 7Á8 units/patient, P = 0 < 01), with a lower proportion of patients receiving any plasma in the test period (55Á4% vs. 44Á7%, P < 0Á01). The proportions of haematology/oncology (control = 33Á3% vs. test = 26Á1%, P = 0Á01) and cardiac surgery patients (control = 71Á3% vs. test = 52Á9%, P < 0Á01) that received any plasma units were less during the test period, and cardiac surgery patients received a lower mean number of plasma units 
(control = 7Á7 vs. test = 5Á3, P < 0Á01). The proportions of paediatric and neonatal patients that received plasma were not significantly different during the two periods; however, the paediatric patients received fewer plasma units per patient (control = 3Á1 vs. test = 1Á8, P = 0Á04) ( Table 4) . Overall, SD plasma comprised 36% and 35% of plasma units transfused in the control and test periods, respectively.
Transfusion-related adverse events
Transfusion-related AE following PC transfusion were infrequent, and not different between the control and test periods per patient or per transfusion (Table 5 ). 1Á3% of patients in the control period (24/1797 patients) and 1Á4% in the test period (23/1694 patients) experienced an AE (P = 1Á00). On a per-transfusion basis, 32 of the 8611 (0Á4%) control transfusions and 24 of 7705 (0Á3%) test transfusions were associated with an AE (P = 0Á59) ( Table 5 ). When patient subpopulations were evaluated for AE frequency, no differences were observed in AE rate between the two periods (Table 5) . Haematology/oncology patients (control = 4Á2% vs. test = 4Á4%, P = 0Á88) and paediatric patients (control = 3Á8% vs. test = 4Á6%, P = 0Á77) demonstrated a greater probability of experiencing an AE than the total population. Only one AE was reported in cardiac surgery patients, occurring during the test period. No AE were reported in either the control or test period in neonatal patients. When AE were evaluated on a per-transfusion basis, again no differences were observed for the general population or for the individual subgroups. Paediatric patients experienced a greater AE rate when compared with adults and these were mostly children in the haematology/oncology departments (data not shown) ( Table 5 ). Most AE were described by the responsible attending physician from the blood bank as mild. The most common clinical characteristic of AE on a per-patient basis were urticaria (0Á6% vs. 0Á9%); chills (0Á4% vs. 0Á2%); and pruritus (0Á4% vs. 0Á1%), for the control and test periods, respectively. Similarly, on a per-transfusion basis, the most frequently observed AE was urticaria (control = 0Á1% vs test = 0Á2%), chills (0Á1% in each period) and pruritus (control = 0Á1% vs test = <0Á1%) (data not shown). No patient experienced a life-threatening event attributed by physicians to platelet transfusion. No cases of TRALI, TA-GVHD, transfusion-related sepsis, transfusion-transmitted viral infections or any deaths were attributed to PC transfusion.
Discussion
Innsbruck began routine use of PI-PC in early 2013 following manufacturing authorization by the Austrian 
Haematology/oncology 522 452 Agency for Health and Food Safety Ltd. (Agentur f€ ur Gesundheit und Ern€ ahrungssicherheit GmbH (AGES)). As part of our ongoing haemovigilance programme, we examined the impact on PC, RCC and plasma utilization, and on transfusion-related AE. The study focused on two 21-month periods, one immediately before implementation of PI and the other starting after a 3-month period during which PI was fully deployed. The comparison assessed the impact on the general population and patient subgroups: haematology/oncology, cardiac surgery patients, paediatric patients and neonates. Patient demographics were similar between treatment periods: almost half were 65 years or older,~8% were paediatric and~1% were neonates. The last two subgroups are informative because children are rarely included in controlled trials. Platelet concentrates transfused during the control period were slightly fresher than in the test period (control 3Á4 vs. test 3Á5 days; P < 0Á01). The higher proportion of PC stored greater than 5 days during the test period (control 9Á5% vs. test 15Á5%, P < 0Á01) reflects the impact of PI-PC that avoids secondary bacterial culture to extend storage and an increased confidence in older platelets with a highly effective intervention against bacterial contamination [7] . The trend of older platelets in the test period was seen in all the subpopulations except the cardiac surgery group that revealed the same mean age of PC between the periods. Cardiac surgery patients are mostly transfused during elective surgery on weekdays when fresher PC were available.
Platelet concentrates utilization showed similar mean values for the support of all patients during both periods, at 4Á8 -9Á7 and 4Á5 -8Á9 PC units/per patient for control and test, respectively. We did not routinely measure the postamotosalen/UVA treatment platelet content of either apheresis or BC PC; however, the pretreatment content was not materially different between the periods. We aimed for an average dose of~3Á0 9 10^11 platelets for both apheresis and BC platelets during both periods. Therefore, the increased proportion of BC platelets used in the test period is not thought to be material but triggered by a shrinking number of apheresis donors within the area accessible to the UHI. We also did not calculate the CCI in routine practice, nevertheless, the 5-10% loss of platelets usually attributed to the amotosalen/UVA treatment did not [3, 8, 9 ] translate into a need for additional PC in the test period. The frequency distributions of the number of PC per patient and the mean intertransfusion interval were not different between the two periods; however, the days of PC support (Table 3) and number of courses of PC support were less in the test period. The days of support in the haematology/oncology and paediatric subgroups and the total numbers of PC transfused in the paediatrics group were less, probably due to fewer transfusions given to paediatric haematology/oncology patients. Taken together, there was no evidence that the introduction of PI caused an increase in PC use, or frequency or duration of use, in any population.
Red cell concentrate component utilization was comparable between the two time periods in patients receiving PC transfusions in the general population, and in all subpopulations, suggesting that the use of PI-PC did not lead to increased bleeding requiring transfusion (Table 4) . Interestingly, the mean number of plasma units transfused was lower during the test period overall and in the cardiac surgery and paediatric subgroups, respectively (Table 4) . During the test period, a significantly smaller proportion of the haematology/oncology (control = 33Á3% vs. test = 26Á1%, P = 0Á01) and cardiac surgery (control = 71Á3% vs. test = 52Á9%, P < 0Á01) subgroups received plasma transfusion (data not shown).
Taken together, our data support the conclusion that PI-treated platelets are equivalent to conventional platelets for prophylaxis to prevent haemorrhage. We show that haematology/oncology patients who often received multiple units of prophylactic PC to support repeated periods of chemotherapy-induced thrombocytopaenia utilized similar numbers of PC with no change in the PC intertransfusion interval or RCC use. These patients required fewer days of PC support. In addition, our findings in cardiac surgery patients support the use of PI-PC for the treatment of active haemorrhage. Cardiac surgery patients usually require one or more PC on the day of surgery to treat active surgical bleeding. The use of cardiac bypass is known to cause extended bleeding times and is associated with increased post-operative haemorrhage in patients with normal peripheral blood platelet counts. Hypothermia and heparin treatment are strongly inhibitory on platelet aggregation [10, 11] , and intraoperative cell salvage may cause acute platelet depletion [12] . Moreover, the increasingly frequent use of aspirin and P2Y 12 inhibitors, such as clopidogrel, prasugrel and ticagrelor in acute coronary syndromes [13] , often results in severe platelet inhibition during cardiac surgery. Multiple PC transfusions are often given in an attempt to reverse the acquired functional platelet defects. Despite these challenges, there was no change in PC and RCC utilization in the test period when PI-PC was utilized, and the frequency of plasma component use decreased, perhaps related to the increased use of thromboelastometry.
Transfusion-related AE (Table 5) were infrequent and not different between the control and test periods. PC's were suspended in SSP+ PAS during both time periods, likely contributing to the low rate of AE's reported. No cases of transfusion-transmitted infection, TRALI, TA-GVHD or deaths associated with PC transfusions were reported in either period, and the clinical characteristics of the AE were mild and consistent with reactions observed after conventional PC transfusions. These observations add to the growing body of haemovigilance data attesting to the safety of PI-PC [14, 15] and extend these findings to 130 paediatric (including 20 neonatal patients), most of whom (59Á9%) received platelets for haematology/oncology or cardiac surgery (23Á8%) indications during the test period.
Overall, our utilization observations are in line with previously published comparative effectiveness studies conducted in Mt.Godinne, Belgium and in EFS Alsace, France (Table 6 ). Osselaer et al. [4] . described a single tertiary-care hospital experience over 2-3-year time periods in Belgium where prospectively gathered data revealed no change in PC use per patient after implementation of amotosalen/UVA, measured as number of PC transfusions; days of PC support; or the total platelet dose transfused, either in the entire hospital or the haematology and oncology subgroups. RCC utilization was also not different, suggesting no change in haemorrhage episodes requiring transfusion. Similarly, a retrospective review of PC and RCC utilization after the introduction of amotosalen/UVA treatment in the EFS Alsace Region of France revealed no change in the total dose of PC and RCC used and a reduction in the incidence of adverse reactions [5] . Having performed in three different countries, in different types of institutions, with varying logistical infrastructure and practices, these studies argue strongly for the lack of impact of the amotosalen/UVA on PC, RCC and plasma utilization, on the comparability of transfusion-related AE, and suggest that the results may be generalizable to other institutions. This is in keeping with the overall picture emerging from the use of the amotosalen/UVA for PC after nationwide adoption in Switzerland, where the utilization of PI-PC was consistent with conventional PC use in the years prior to adoption, and RCC use was reduced and plasma use remained constant. In Switzerland, in contrast to UHI and similar to EFS Alsace, a significant reduction of AE was observed over the 4 years after adoption, probably due to the concurrent introduction of PAS [16] .
Comparative effectiveness analysis of PI-PC using the commercialized product under local logistical constraints, and with the application of pragmatic clinical choices in order to best support local patients, adds considerably to the growing experience with the amotosalen/UVA. Unlike randomized controlled trials that usually involve a defined patient population with stringent inclusions and exclusions, in comparative effectiveness studies all patients are included and assessment in routine use is possible. One limitation is that such studies are retrospective and observational in nature, and we were unable to Table 6 Comparative effectiveness of amotosalen/UVA-treated and conventional components Mt Godinne, Belgium [4] EFS Alsace, France [5] Innsbruck, Austria control for changes in clinical practice that were not monitored. Nevertheless, in this study, we show that manufacturing of PI-PC is compatible within the routine operations of our large regional centre and its implementation did not significantly affect the utilization of blood products or alter the efficacy and safety profile of PC transfusions across a broad spectrum of adult and paediatric patients.
